117 related articles for article (PubMed ID: 36773290)
1. Plasma concentrations of glucagon and glucagon-like peptide-1 are reduced in dogs with aminoaciduric canine hypoaminoacidemic hepatopathy syndrome versus healthy dogs: a preliminary study.
Holm SM; Peng SA; Holter MM; Cummings BP; Loftus JP
Am J Vet Res; 2023 Apr; 84(4):. PubMed ID: 36773290
[TBL] [Abstract][Full Text] [Related]
2. Plasma glucagon-like peptide-2 concentrations are lower in dogs with chronic enteropathies than in healthy dogs.
Riehm MD; Mayhue EJ; Jugan MC
Am J Vet Res; 2023 Nov; 84(11):. PubMed ID: 37657734
[TBL] [Abstract][Full Text] [Related]
3. Untargeted metabolomic profiles reveal widespread metabolic perturbations and identify candidate biomarkers in aminoaciduric canine hypoaminoacidemic hepatopathy syndrome.
Loftus JP; Rubio MED; Yant J; Bichoupan A; Zhang S; Miller AJ; Center SA; Ruiz MDR; Macho LP
Am J Vet Res; 2023 Dec; 84(12):. PubMed ID: 37871610
[TBL] [Abstract][Full Text] [Related]
4. Venous blood provides lower glucagon-like peptide-1 concentrations than arterialized blood in the postprandial but not the fasted state: Consequences of sampling methods.
Chen YC; Edinburgh RM; Hengist A; Smith HA; Walhin JP; Betts JA; Thompson D; Gonzalez JT
Exp Physiol; 2018 Sep; 103(9):1200-1205. PubMed ID: 29947441
[TBL] [Abstract][Full Text] [Related]
5. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon.
Jeppesen PB; Hartmann B; Thulesen J; Hansen BS; Holst JJ; Poulsen SS; Mortensen PB
Gut; 2000 Sep; 47(3):370-6. PubMed ID: 10940274
[TBL] [Abstract][Full Text] [Related]
6. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.
Gutniak MK; Larsson H; Sanders SW; Juneskans O; Holst JJ; Ahrén B
Diabetes Care; 1997 Dec; 20(12):1874-9. PubMed ID: 9405910
[TBL] [Abstract][Full Text] [Related]
8. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
9. Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls.
Zibar K; Ćuća JK; Blaslov K; Bulum T; Smirčić-Duvnjak L
Ann Clin Biochem; 2015 Mar; 52(Pt 2):220-5. PubMed ID: 25005458
[TBL] [Abstract][Full Text] [Related]
10. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
[TBL] [Abstract][Full Text] [Related]
11. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
[TBL] [Abstract][Full Text] [Related]
12. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
13. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
Willms B; Idowu K; Holst JJ; Creutzfeldt W; Nauck MA
Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239
[TBL] [Abstract][Full Text] [Related]
14. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.
Kielgast U; Holst JJ; Madsbad S
Diabetes; 2011 May; 60(5):1599-607. PubMed ID: 21441444
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and amino acid profiles of dogs with hepatocutaneous syndrome or hepatocutaneous-associated hepatopathy.
Loftus JP; Center SA; Astor M; Miller AJ; Peters-Kennedy J
J Vet Intern Med; 2022 Jan; 36(1):97-105. PubMed ID: 34477245
[TBL] [Abstract][Full Text] [Related]
16. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2011 Feb; 96(2):447-53. PubMed ID: 21047927
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans.
Meier JJ; Gethmann A; Götze O; Gallwitz B; Holst JJ; Schmidt WE; Nauck MA
Diabetologia; 2006 Mar; 49(3):452-8. PubMed ID: 16447057
[TBL] [Abstract][Full Text] [Related]
19. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.
Schirra J; Nicolaus M; Roggel R; Katschinski M; Storr M; Woerle HJ; Göke B
Gut; 2006 Feb; 55(2):243-51. PubMed ID: 15985560
[TBL] [Abstract][Full Text] [Related]
20. Relationship between metabolic syndrome and meal-induced glucagon like peptide-1 response in type 1 diabetic patients1-1.
Blaslov K; Bulum T; Zibar K; Duvnjak L
J Diabetes; 2015 May; 7(3):340-6. PubMed ID: 25042812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
